Emerging evidence shows autoantibodies may drive neuropathic pain, suggesting immune profiling can improve treatment.
Emerging evidence, supported by clinical responses to immunotherapy and the recapitulation of sensory symptoms in passive transfer models, shows that autoantibodies (AAbs) may drive neuropathic pain. These findings highlight the importance of immune profiling to enhance diagnosis and treatment, and provide molecular insights into broader pain mechanisms in clinical contexts.
No takes yet. Share an insight, caveat, or question.
Farah et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: